MedPath

Post-trial observational study for a phase II study of accelerator-BNCT for head and neck cancer (JHN002): JHN002 Look Up Study

Not Applicable
Conditions
nresectable locally recurrent head and neck squamous cell carcinoma Unresectable head and neck non-squamous cell carcinoma
Registration Number
JPRN-UMIN000040501
Lead Sponsor
Southern Tohoku BNCT Research Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
21
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients unable to comply with the protocol and to attend follow-up visits (because of mental, family, social, geographical, or other reasons).

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-Locoregional progression-free survival Time from the date of BNCT to first documented disease progression in locoregional area.
Secondary Outcome Measures
NameTimeMethod
-Efficacy -Duration of response The duration of the response is the time from the confirmed achievement of CR or PR (whichever is recorded first) to the date of initial objectively confirmed recurrence or exacerbation. -Response The objective tumor response within 2 years of BNCT is evaluated using RECIST guidelines (version 1.1). Change in tumor size is evaluated as the proportion of tumo size in target lesions compared to baseline before BNCT. -Overall survival Time from the date of BNCT todeath from any cause up to the completion of the survival survey period. -Safety -Adverse events Incidence and grading in the observation period
© Copyright 2025. All Rights Reserved by MedPath